Stranger things have happened, I do think AGGX has IP which may be of value to another company with better financing and the inclination to move it through clinical trials. If not a buyout, the best way forward would be for management to buy a clean shell and do a reverse-merger where AGGX shareholders get shares of the new controlling entity.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.